Sound View Wealth Advisors Group LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 0.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 120,966 shares of the biopharmaceutical company’s stock after buying an additional 295 shares during the quarter. Sound View Wealth Advisors Group LLC’s holdings in Pfizer were worth $4,383,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of New York Mellon Corp grew its position in shares of Pfizer by 12.1% during the 4th quarter. Bank of New York Mellon Corp now owns 64,756,839 shares of the biopharmaceutical company’s stock worth $2,383,700,000 after buying an additional 6,965,496 shares in the last quarter. Norges Bank bought a new stake in Pfizer during the fourth quarter valued at about $2,219,532,000. Morgan Stanley boosted its position in Pfizer by 16.4% during the fourth quarter. Morgan Stanley now owns 53,610,111 shares of the biopharmaceutical company’s stock valued at $1,973,389,000 after purchasing an additional 7,540,245 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Pfizer by 5.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 42,009,283 shares of the biopharmaceutical company’s stock valued at $1,546,362,000 after purchasing an additional 2,012,367 shares in the last quarter. Finally, Sanders Capital LLC boosted its position in Pfizer by 10.6% during the fourth quarter. Sanders Capital LLC now owns 31,947,816 shares of the biopharmaceutical company’s stock valued at $1,280,997,000 after purchasing an additional 3,051,838 shares in the last quarter. 67.36% of the stock is currently owned by institutional investors and hedge funds.
PFE traded up $0.23 during trading on Tuesday, hitting $40.06. The company’s stock had a trading volume of 1,086,543 shares, compared to its average volume of 31,749,029. The company has a current ratio of 1.40, a quick ratio of 1.13 and a debt-to-equity ratio of 0.76. Pfizer Inc. has a twelve month low of $31.61 and a twelve month high of $43.08. The business’s fifty day simple moving average is $37.02 and its 200 day simple moving average is $36.78. The firm has a market capitalization of $223.44 billion, a price-to-earnings ratio of 25.70, a P/E/G ratio of 2.79 and a beta of 0.70.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.04). Pfizer had a net margin of 17.85% and a return on equity of 24.88%. The business had revenue of $11.68 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same period in the previous year, the business posted $0.55 earnings per share. The firm’s revenue for the quarter was up 11.8% on a year-over-year basis. As a group, equities research analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 4th. Stockholders of record on Friday, May 7th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.89%. The ex-dividend date of this dividend is Thursday, May 6th. Pfizer’s dividend payout ratio is presently 52.88%.
A number of equities research analysts have commented on the company. TheStreet cut Pfizer from a “b” rating to a “c+” rating in a research note on Friday, March 5th. Royal Bank of Canada assumed coverage on Pfizer in a research note on Wednesday, April 7th. They issued a “sector perform” rating and a $42.00 price target for the company. JPMorgan Chase & Co. set a $36.00 price target on Pfizer and gave the company a “neutral” rating in a research note on Wednesday, February 3rd. SVB Leerink decreased their price target on Pfizer from $40.00 to $39.00 and set a “market perform” rating for the company in a research note on Thursday, April 1st. Finally, Berenberg Bank restated a “neutral” rating and issued a $38.00 price objective on shares of Pfizer in a research note on Tuesday, March 23rd. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $38.47.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Further Reading: Learning About the VIX – Volatility Index
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.